NABP Testifies on Drug Supply Chain Threats and New Digital Safety Tools

The U.S. House Committee on Energy and Commerce convened on June 12, 2025, to address pressing issues surrounding domestic manufacturing and the health care supply chain, with a particular focus on the pharmaceutical sector. The meeting highlighted the critical need for strengthening the U.S. supply chain to ensure the safety and availability of medications for American patients.

One of the key discussions centered on the Drug Supply Chain Security Act (DSCSA), which was enacted in 2013 to enhance the safety of the pharmaceutical supply chain. The National Association of Boards of Pharmacy (NABP) reported significant progress in implementing the DSCSA, including the launch of a new digital platform called Pulse. This platform aims to improve data sharing and tracking of medications, allowing regulators and pharmacies to verify the legitimacy of products and identify counterfeit medications. Since its rollout, nearly 30 states have begun utilizing Pulse, demonstrating a collaborative effort to combat illegal activities within the supply chain.

However, the meeting also underscored ongoing challenges. NABP representatives warned that a staggering 96% of online pharmacies operate illegally, misleading consumers into believing that their medications are safe and regulated. This misinformation poses a serious risk to public health, as many Americans are unaware of the dangers associated with purchasing medications online. The committee heard alarming accounts of unregulated operations, such as a med spa compounding medications in unsanitary conditions, further illustrating the vulnerabilities within the current system.

The discussion also touched on the broader implications of U.S. reliance on foreign pharmaceutical manufacturing, particularly from countries like China. Lawmakers expressed concerns that this dependency compromises national security and public health. The committee emphasized the importance of prioritizing American-made pharmaceuticals, with testimonies highlighting the role of domestic manufacturers like U.S. Antibiotics, which produces essential medications and supports local jobs.

As the meeting concluded, committee members reiterated their commitment to bolstering domestic manufacturing and ensuring that American patients have access to safe and effective medications. The discussions reflect a growing recognition of the need for a robust and secure health care supply chain, one that prioritizes public safety and supports local economies. The outcomes of this meeting may pave the way for future legislative efforts aimed at enhancing the integrity of the pharmaceutical supply chain and protecting the health of communities across the nation.